Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Cristina Jimenez Ortigosa"'
Autor:
Kelley R. Healey, Padmaja Paderu, Xin Hou, Cristina Jimenez Ortigosa, Nicole Bagley, Biren Patel, Yanan Zhao, David S. Perlin
Publikováno v:
Journal of Fungi, Vol 6, Iss 3, p 143 (2020)
Invasive infections caused by the opportunistic pathogen Candida glabrata are treated with echinocandin antifungals that target β-1,3-glucan synthase, an enzyme critical for fungal cell wall biosynthesis. Echinocandin resistance develops upon mutati
Externí odkaz:
https://doaj.org/article/167ff5ae15ea416fa5cd371c81c5239e
Autor:
Rocio Garcia-Rubio, Cristina Jimenez-Ortigosa, Lucius DeGregorio, Christopher Quinteros, Erika Shor, David S. Perlin
Publikováno v:
mBio, Vol 12, Iss 4 (2021)
ABSTRACT Fungal infections cause significant mortality and morbidity worldwide, and the limited existing antifungal reservoir is further weakened by the emergence of strains resistant to echinocandins, a first line of antifungal therapy. Candida glab
Externí odkaz:
https://doaj.org/article/0355009511bd4f31a5ba13af1c8e147f
Autor:
Kelley R. Healey, Yanan Zhao, Winder B. Perez, Shawn R. Lockhart, Jack D. Sobel, Dimitrios Farmakiotis, Dimitrios P. Kontoyiannis, Dominique Sanglard, Saad J. Taj-Aldeen, Barbara D. Alexander, Cristina Jimenez-Ortigosa, Erika Shor, David S. Perlin
Publikováno v:
Nature Communications, Vol 7, Iss 1, Pp 1-10 (2016)
The fungal pathogen Candida glabrata readily acquires resistance to multiple types of antifungal drugs. Here, Healey et al. show that C. glabrataclinical isolates often carry mutations in a gene involved in DNA mismatch repair, and this is associated
Externí odkaz:
https://doaj.org/article/1815c031c89a4873a9003da52493606b
Autor:
João Nobrega de Almeida, Cristina Jimenez-Ortigosa, Elaine Cristina Francisco, Arnaldo L. Colombo, David S. Perlin
Publikováno v:
Antimicrob Agents Chemother
We analyzed a cohort of Trichosporon asahii strains with different MICs of fluconazole and voriconazole and evaluated the presence of ERG11 mutations. ERG11 mutation conferring an amino acid change was found and its resistance potential was evaluated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0872b32e2c113bcbbc0f7aca7137a593
https://doi.org/10.1128/aac.01101-22
https://doi.org/10.1128/aac.01101-22
Autor:
Cristina Jimenez-Ortigosa, Christopher Quinteros, David S. Perlin, Lucius DeGregorio, Rocio Garcia-Rubio, Erika Shor
Publikováno v:
mBio
mBio, Vol 12, Iss 4 (2021)
mBio, Vol 12, Iss 4 (2021)
Fungal infections cause significant mortality and morbidity worldwide, and the limited existing antifungal reservoir is further weakened by the emergence of strains resistant to echinocandins, a first line of antifungal therapy. Candida glabrata is a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3da9c2762df12733c19a3cf8c4ae6613
http://europepmc.org/articles/PMC8406274
http://europepmc.org/articles/PMC8406274
Autor:
Yanan, Zhao, Min Hee, Lee, Padmaja, Paderu, Annie, Lee, Cristina, Jimenez-Ortigosa, Steven, Park, Robert S, Mansbach, Karen Joy, Shaw, David S, Perlin
Publikováno v:
Antimicrobial agents and chemotherapy. 62(10)
APX001 is a first-in-class, intravenous and orally available, broad-spectrum antifungal agent in clinical development for the treatment of life-threatening invasive fungal infections. The half-life of APX001A, the active moiety of APX001, is signific
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d5c1f62093e25d4bd7122c3a671eddf5
https://pubmed.ncbi.nlm.nih.gov/30012766
https://pubmed.ncbi.nlm.nih.gov/30012766
Autor:
Roxana G. Vitale, Guillermo Garcia-Effron, Soledad Gamarra, Javier Afeltra, Cristina Jimenez-Ortigosa, David S. Perlin, Catiana Dudiuk, Florencia Leonardeli
Publikováno v:
CONICET Digital (CONICET)
Consejo Nacional de Investigaciones Científicas y Técnicas
instacron:CONICET
Consejo Nacional de Investigaciones Científicas y Técnicas
instacron:CONICET
Clinical echinocandin resistance among Candida glabrata strains is increasing, especially in the United States. Antifungal susceptibility testing is considered mandatory to guide therapeutic decisions. However, these methodologies are not routinely p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13e4f55c4fd7640e8f25b8a5fc3cf8dd
MK-3118 is as an orally active new antifungal in the early stage of clinical development that inhibits the biosynthesis of β-(1,3)-glucan. We evaluated the in vitro activity of this compound against wild-type and echinocandin-resistant (ER) isolates
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fdc6a9c568104b610c222c23b30d649e
https://europepmc.org/articles/PMC3910825/
https://europepmc.org/articles/PMC3910825/
Autor:
Giovanni Luis Breda, David S. Perlin, Cristina Jimenez-Ortigosa, Ana Carolina Remondi Souza, Arnaldo Lopes Colombo, Fernando César Bizerra, Flavio Queiroz-Telles
Publikováno v:
Antimicrobial agents and chemotherapy. 58(4)
We identified a case of breakthrough candidemia in a 25-year-old patient receiving micafungin prophylaxis (50 mg/day). Five Candida glabrata isolates were obtained from blood cultures and were classified as multidrug-resistant isolates, since all of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2895815b6b847f6c8711fe44710eccb
https://pubmed.ncbi.nlm.nih.gov/24468776
https://pubmed.ncbi.nlm.nih.gov/24468776
Autor:
Xin Hou, Kelley R. Healey, Erika Shor, Milena Kordalewska, Cristina Jiménez Ortigosa, Padmaja Paderu, Meng Xiao, He Wang, Ying Zhao, Li-Yan Lin, Yan-Hai Zhang, Yong-Zhe Li, Ying-Chun Xu, David S. Perlin, Yanan Zhao
Publikováno v:
Emerging Microbes and Infections, Vol 8, Iss 1, Pp 1619-1625 (2019)
ABSTRACTEchinocandin resistance in Candida glabrata poses a serious clinical challenge. The underlying resistance mechanism of a pan-echinocandin-resistant C. glabrata isolate (strain L74) was investigated in this study. FKS mutants carrying specific
Externí odkaz:
https://doaj.org/article/4617bf9f1b1d4a9d867399b3ce74b219